Ajax Therapeutics shared a post on LinkedIn:
“We are happy to announce this morning that Eli Lilly and Company will acquire Ajax Therapeutics.
Lilly will be able to accelerate the development of AJ1-11095, the first Type II JAK2 inhibitor to go into the clinic for patients with myeloproliferative neoplasms.
We are grateful to scientific colleagues, investors who saw the potential for this approach to make a difference for patients with a difficult group of diseases, committed clinical investigators in the US and Europe, and most importantly patients who have participated in the AJX-101 trial (NCT06343805).
Other articles from Ajax Therapeutics.